The Latest Breaking News from ACADIA Pharmaceuticals

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Scientists are cautiously optimistic that new approaches to treating the disabling condition may improve the lives of those affected by it

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06 million.

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that ACADIA Pharmaceuticals will report an earnings per share (EPS) of $-0.60.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:

Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $130.76 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 198.08%, resulting in a loss of $43.09 million.